Stock Analysis
UV Germi (EPA:ALUVI) Full Year 2023 Results
Key Financial Results
- Revenue: €8.48m (up 16% from FY 2022).
- Net income: €290.1k (up 340% from FY 2022).
- Profit margin: 3.4% (up from 0.9% in FY 2022). The increase in margin was driven by higher revenue.
All figures shown in the chart above are for the trailing 12 month (TTM) period
UV Germi shares are up 8.0% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 2 warning signs for UV Germi that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether UV Germi is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ALUVI
UV Germi
UV Germi SA designs, manufactures, and sells ultraviolet devices for the treatment of, air, water, and surfaces in France.
Solid track record with excellent balance sheet.